S&P 500   4,547.49 (-0.43%)
DOW   36,044.28 (-0.22%)
QQQ   385.43 (-0.48%)
AAPL   192.41 (-0.52%)
MSFT   369.35 (-0.85%)
META   318.11 (-0.06%)
GOOGL   130.24 (-0.57%)
AMZN   144.61 (-1.55%)
TSLA   240.24 (+0.64%)
NVDA   457.10 (-1.84%)
NIO   7.83 (+5.38%)
BABA   71.75 (-0.87%)
AMD   117.16 (-1.03%)
T   17.00 (-1.28%)
F   10.69 (+0.85%)
MU   73.00 (-0.94%)
CGC   0.70 (+4.73%)
GE   120.08 (-0.12%)
DIS   91.38 (+0.65%)
AMC   6.81 (-2.99%)
PFE   28.74 (-1.20%)
PYPL   59.42 (+2.59%)
XOM   99.11 (-1.32%)
S&P 500   4,547.49 (-0.43%)
DOW   36,044.28 (-0.22%)
QQQ   385.43 (-0.48%)
AAPL   192.41 (-0.52%)
MSFT   369.35 (-0.85%)
META   318.11 (-0.06%)
GOOGL   130.24 (-0.57%)
AMZN   144.61 (-1.55%)
TSLA   240.24 (+0.64%)
NVDA   457.10 (-1.84%)
NIO   7.83 (+5.38%)
BABA   71.75 (-0.87%)
AMD   117.16 (-1.03%)
T   17.00 (-1.28%)
F   10.69 (+0.85%)
MU   73.00 (-0.94%)
CGC   0.70 (+4.73%)
GE   120.08 (-0.12%)
DIS   91.38 (+0.65%)
AMC   6.81 (-2.99%)
PFE   28.74 (-1.20%)
PYPL   59.42 (+2.59%)
XOM   99.11 (-1.32%)
S&P 500   4,547.49 (-0.43%)
DOW   36,044.28 (-0.22%)
QQQ   385.43 (-0.48%)
AAPL   192.41 (-0.52%)
MSFT   369.35 (-0.85%)
META   318.11 (-0.06%)
GOOGL   130.24 (-0.57%)
AMZN   144.61 (-1.55%)
TSLA   240.24 (+0.64%)
NVDA   457.10 (-1.84%)
NIO   7.83 (+5.38%)
BABA   71.75 (-0.87%)
AMD   117.16 (-1.03%)
T   17.00 (-1.28%)
F   10.69 (+0.85%)
MU   73.00 (-0.94%)
CGC   0.70 (+4.73%)
GE   120.08 (-0.12%)
DIS   91.38 (+0.65%)
AMC   6.81 (-2.99%)
PFE   28.74 (-1.20%)
PYPL   59.42 (+2.59%)
XOM   99.11 (-1.32%)
S&P 500   4,547.49 (-0.43%)
DOW   36,044.28 (-0.22%)
QQQ   385.43 (-0.48%)
AAPL   192.41 (-0.52%)
MSFT   369.35 (-0.85%)
META   318.11 (-0.06%)
GOOGL   130.24 (-0.57%)
AMZN   144.61 (-1.55%)
TSLA   240.24 (+0.64%)
NVDA   457.10 (-1.84%)
NIO   7.83 (+5.38%)
BABA   71.75 (-0.87%)
AMD   117.16 (-1.03%)
T   17.00 (-1.28%)
F   10.69 (+0.85%)
MU   73.00 (-0.94%)
CGC   0.70 (+4.73%)
GE   120.08 (-0.12%)
DIS   91.38 (+0.65%)
AMC   6.81 (-2.99%)
PFE   28.74 (-1.20%)
PYPL   59.42 (+2.59%)
XOM   99.11 (-1.32%)

Harpoon Therapeutics Stock Price, News & Analysis (NASDAQ:HARP)

$9.67
-0.95 (-8.95%)
(As of 03:44 PM ET)
Compare
Today's Range
$9.51
$11.50
50-Day Range
$3.29
$12.99
52-Week Range
$3.11
$33.55
Volume
187,591 shs
Average Volume
70,955 shs
Market Capitalization
$163.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50

Harpoon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
202.9% Upside
$29.50 Price Target
Short Interest
Healthy
1.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
1.22mentions of Harpoon Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.93) to ($3.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

168th out of 953 stocks

Biological Products, Except Diagnostic Industry

20th out of 148 stocks


HARP stock logo

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

HARP Stock Price History

HARP Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Harpoon Therapeutics Announces Private Placement Of Up To $150 Mln
See More Headlines
Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/25/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.50
High Stock Price Target
$45.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+168.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-67,730,000.00
Pretax Margin
-81.67%

Debt

Sales & Book Value

Annual Sales
$37.34 million
Book Value
$1.63 per share

Miscellaneous

Free Float
14,054,000
Market Cap
$186.08 million
Optionable
Not Optionable
Beta
2.10
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report














HARP Stock Analysis - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HARP shares.
View HARP analyst ratings
or view top-rated stocks.

What is Harpoon Therapeutics' stock price target for 2024?

5 analysts have issued 12-month price objectives for Harpoon Therapeutics' stock. Their HARP share price targets range from $13.00 to $45.00. On average, they predict the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 202.9% from the stock's current price.
View analysts price targets for HARP
or view top-rated stocks among Wall Street analysts.

How have HARP shares performed in 2023?

Harpoon Therapeutics' stock was trading at $7.2570 at the beginning of the year. Since then, HARP shares have increased by 34.2% and is now trading at $9.74.
View the best growth stocks for 2023 here
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 255,300 shares, an increase of 7.2% from the October 31st total of 238,200 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.9% of the company's stock are short sold.
View Harpoon Therapeutics' Short Interest
.

When is Harpoon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our HARP earnings forecast
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($3.09) by $2.63. The company earned $4.45 million during the quarter, compared to analyst estimates of $8.33 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%.

When did Harpoon Therapeutics' stock split?

Harpoon Therapeutics's stock reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include MPM Bioimpact LLC (8.24%), Kennedy Capital Management LLC (1.37%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt.
View institutional ownership trends
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HARP) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -